TVRD — Tvardi Therapeutics, Inc.

Cara Therapeutics Q4 2023 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Q4 2023 revenue was $3 million, a slight decrease from $3.3 million in Q4 2022. This included $2.3 million from collaborative revenue related to KORSUVA injection and $0.7 million from royalties and milestone payments.
• KORSUVA Injection Sales: Generated net sales of $5 million in Q4, with a 22% quarter-over-quarter increase in demand reflected by wholesaler shipments.
• Expenses: R&D expenses rose to $28.4 million from $26 million year-over-year, primarily due to increased clinical trial costs. G&A expenses remained stable at $6.6 million.
• Cash Position: As of December 31, 2023, cash, cash equivalents, and marketable securities totaled $100.8 million, down from $156.7 million in 2022, largely due to $92.1 million used in operating activities. The company expects this cash to fund operations into 2026.

2. Strategic Updates and Business Highlights

• Focus on Notalgia Paresthetica (NP): Cara has prioritized the development of oral difelikefalin for NP, a condition with significant unmet medical need and no approved treatments. This strategic shift is expected to extend the company's cash runway and enhance the likelihood of clinical and commercial success.
• Clinical Development: Enrollment in the Phase 2/3 COURAGE I study was completed ahead of schedule, with top-line efficacy and safety results expected in Q3 2024. The study aims to identify the optimal dose for further development.
• Market Opportunity: Approximately 650,000 patients in the U.S. are diagnosed with NP, highlighting a substantial market opportunity for an effective treatment.

3. Forward Guidance and Outlook

• Clinical Milestones: The company anticipates reporting results from the COURAGE I study in Q3 2024, which will inform the design of the Phase 3 pivotal study.
• Cash Runway: Cara's current financial position is expected to support operations and clinical development through 2026, allowing for completion of key clinical milestones.

4. Bad News, Challenges, or Points of Concern

• KORSUVA Injection Challenges: Despite growth in demand, expected unfavorable reimbursement changes following the end of the TDAPA period may restrict access to KORSUVA, leading to limited revenue contributions going forward.
• Market Risks: The company faces risks related to the clinical development of oral difelikefalin, including potential variability in placebo response rates and the need for successful trial outcomes to validate its strategy.

5. Notable Q&A Insights

• Clinical Program Size: The size of the Phase 3 program will be determined based on results from the ongoing trial, with a preference for selecting a single dose for simplicity.
• Part A Expectations: The company is cautious about expectations for the upcoming data readout, anticipating a potentially higher placebo response due to study design changes and increased awareness.
• Partnership Opportunities: While there is interest in potential partnerships, the company intends to focus on completing the NP program independently given its current cash position and strategic priorities.
• Quality of Life Measures: There is ongoing work to identify appropriate quality of life measures for NP patients, as previous studies indicated that existing tools may not be relevant.

Overall, Cara Therapeutics is strategically focusing on the development of oral difelikefalin for NP, with a solid financial position to support its initiatives, despite facing challenges with KORSUVA and the inherent risks of clinical development.